Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease

Movement Disorders

Volumn 23, Issue SUPPL. 3, 2008, Pages

  Obeso, Jose A ^a,b   Rodríguez Oroz, Maria Cruz ^a,b   Benitez Temino, Beatriz ^a   Blesa, Francisco J ^a,b   Guridi, Jorge ^a,b   Marin, Concepció ^b,c   Rodriguez, Manuel ^b,d  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Basal ganglia; Globus pallidus; Medium spiny neurons; Parkinson's disease; Striatum; Subthalamic nucleus

Indexed keywords

ACETYLCHOLINE; DOPAMINE; LEVODOPA;

ACETYLCHOLINE RELEASE; ARTICLE; BASAL GANGLION; BRAIN DEPTH STIMULATION; BRAIN FUNCTION; CELL ACTIVITY; CHOREA; CONCEPT ANALYSIS; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; DRUG SAFETY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FACILITATION; GABAERGIC TRANSMISSION; GLOBUS PALLIDUS; HUMAN; INTERNEURON; LONG TERM DEPRESSION; MOTONEURON; MOTOR CORTEX; MOTOR PERFORMANCE; NERVE CELL NETWORK; NERVE CELL STIMULATION; NEUROANATOMY; NEUROMODULATION; NONHUMAN; PALLIDOTOMY; PARASYMPATHETIC NERVE; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; REFRACTORY PERIOD; SACCADIC EYE MOVEMENT; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SYNAPTIC TRANSMISSION; THALAMOCORTICAL TRACT; THALAMOTOMY;

AFFERENT PATHWAYS; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; CEREBRAL CORTEX; CORPUS STRIATUM; GLOBUS PALLIDUS; HAPLORHINI; HUMANS; MODELS, ANIMAL; MODELS, NEUROLOGICAL; PARKINSON DISEASE;

EID: 53149137434     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22062     Document Type: Article

References (108)

1. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34:295-507.
2. Purdon Martin J, Alcock NS. Hemichorea associated with a lesion of the corpus Luysii. Brain 1934;57:504-516.
3. Carpenter MB, Whittier JR, Mettler FA. Analysis of choreoid hyperkinesia in the rhesus monkey. J Comp Neurol 1950;92: 293-322.
4. Hassler R, Riechert T, Mundinguer F, Umbach W, Ganglberger JA. Physiological observations in stereotaxic operations in extrapyramidal motor disturbances. Brain 1960;83:337-349.
5. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180:1200.
6. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and DA (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960;38:1236-1239. [In German, English translation in Parkinsonism and Related Disorders 1998;4:53-57.]
7. Birkmayer W, Homykiewicz O. The effect of 1-3,4-dihydroxy-phenylalanine (= L-DOPA) on the parkinsonian akinesia. Wien Klin Wochenschr 1961;73:787-788. [In German, English translation in Parkinsonism and Related Disorders 1998;4:59-60.]
8. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
9. Marsden CD. The mysterious motor function of the basal ganglia. Neurology 1982;32:514-539.
10. Alexander GE, DeLong MR, Strick PL, Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 1986;9:357-381.
11. Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Rev 2000;31:236-250.
12. Smith Y, Bevan MD, Shink E, Bolam JP. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 1998;86:353-358.
13. Pasupathy A, Miller EK. Different time courses of learning-related activity in the prefrontal cortex and striatum. Nature 2005;433:873-876.
14. Yin HH, Knowlton B. The role of the basal ganglia in habit formation. Nat Neurosci Rev 2006;7:464-476.
15. Hikosaka O, Nakamura K, Sakai K, Nakahara H. Central mechanisms of motor learning. Curr Opin Neurobiol 2002;12:217-222.
16. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trend Neurosci 1989;12:366-375.
17. Crossman AR. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987;21:1-40.
18. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trend Neurosci 1990;13:281-285.
19. Wichmann T, DeLong MR. Functional and pathophysiological models of the basal ganglia. Curr Opinion Neurobiol 1996;6: 751-758.
20. Obeso JA, Rodriguez MC, DeLong MD. Basal ganglia pathophysiology: a critical review. Adv Neurol 1997;73:3-18.
21. Levy R, Hazrati LN, Herrero MT. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience 1997;76:335-343.
22. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR. Current problems in understanding the basal ganglia model for Parkinson's disease and levodopa-induced dyskinesias. Ann Neurol 2000;47(Suppl. 1):22-32.
23. Takada M, Tokimo H, Nambu A, Inase M. Corticostriatal input zones from the supplementary motor area overlap those from the contra- rather than ipsilateral primary motor cortex. Brain Res 1998;791:335-340.
24. DeLong MR, Georgopoulos AP. Motor functions of the basal ganglia as revealed by studies of single cell activity in the behaving primate. Adv Neurol 1979;24:131-140.
25. Guridi J, Gorospe A, Ramos E, Rodriguez MC, Linazasoro G, Obeso JA. Targeting the basal ganglia for pallidotomy in Parkinson's disease. Neurosurgery 1999;45:278-287.
26. Rodriguez-Oroz MC, Rodriguez M, Guridi J, et al. The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. Brain 2001;124:1777-1790.
27. Theodosopoulos PV, Marks WJ, Jr, Christine C, Starr PA. Locations of movement-related cells in the human subthalamic nucleus in Parkinson's disease. Mov Disord 2003;18:791-798.
28. Hoover JE, Strick PL. Multiple output channels in the basal ganglia. Science 1993;259:819-821.
29. Nambu A, Takada M, Inase M, Tokuno H. Dual somatotopical representations in the primate subthalamic nucleus: evidence for ordered but reversed body-map transformations from the primary motor cortex and the supplementary motor area. J Neurosci 1996; 16:2671-2683.
30. Miyachi S, Lu X, Imanishi M, Sawada K, Nambu A, Takada M. Somatotopically arranged inputs from putamen and subthalamic nucleus to primary motor cortex. Neurosci Res 2006;56: 300-308.
31. Bentivoglio M, Morelli M. The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain. In: Handbook of Chemical Neuroanatomy, Vol. 21. Dopamine, Chap. 1, Elsevier; 2005. p 1-107.
32. Hikosaka O, Wurtz RH. Visual and oculomotor functions of monkey substantia nigra pars reticulata. III. Memory-contingent visual and saccade responses. J Neurophysiol 1983;49:1268-1284.
33. Turner RS, Anderson ME. Context-dependent modulation of movement-related discharge in the primate globus pallidus. J Neurosci 2005;25:2965-2976.
34. Crossman AR. Primate models of movement disorders of basal ganglia origin. Trend Neurosci 1990;13:281-285.
35. Hirsch EC, Périer C, Orieux G, et al. Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci 2000;3: S78-S85.
36. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subdralamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994;72:507-520.
37. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-1438.
38. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesions of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl, 1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 1991;6:288-292.
39. Guridi J, Herrero MT, Luquin MIZ, et al. Subthalamotomy in parkinsonian monkeys: behavioral and biochemical analysis. Brain 1996;119:1717-1728.
40. Samuel M, Ceballos-Baumann O, Tufjanski N, et al. Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements. An H-2 O PET study. Brain 1997;120:1301-1314.
41. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005; 128:2240-2249.
42. Papa SM, Desimone R, Fiorani M, Oldfield EH. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol 1999;46:732-738.
43. Suarez JI, Metman LV, Reich SG, Dougherty PM, Hallett M, Lenz FA. Pallidotomy for hemiballismus: efficacy and characteristics of neuronal activity. Ann Neurol 1997;42:807-811.
44. Vitek JL, Chockkan V, Zhang JY, et al. Neuronat activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 1999;46:22-35.
45. Merello M, Balej J, Deffino M, Cammarota A, Betti O, Leiguarda R. Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease. Mov Disord 1999; 14:45-49.
46. Levesque M, Parent A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. Proc Natl Acad Sci USA 2005;102:11888-1893.
47. Surmeier J, Song W-J, Zhen Y. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 1996;16:6579-6591.
48. Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Di Lazzaro V. Dopamine dependency of oscillations between subdralamic nucleus and pallidum in Parkinson's disease. J Neurosci 2001;21: 1033-1038.
49. Foffani G, Ardolino G, Meda B, Egidi M, Rampini P, Caputo E, Baselli G, Priori A. Altered subthalamo-pallidal synchronisation in parkinsoman dyskinesias. J Neurol Neurosurg Psychiatry 2005;76:426-428.
50. Alonso-Frech F, Zamarbide I, Alegre M, Rodriguez-Oroz MC, Guridi J, Manrique M, Valencia M, Artieda J, Obeso JA. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. Brain 2006;129:1748-1757.
51. Laitinen L, Vilkki J. Measurement of parkinsonian hypokinesia with purdue pegboard and motor reaction time tests. In: Siegfred J, editor. Parkinson's disease, Vol. 1. Berlin-Stugart-Vienna: Verlag Hans Huber; 1973. p 185-192.
52. Marsden CD, Obeso JA. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease, Brain 1994; 117:877-897.
53. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23:S8-S19.
54. Seger CA. The basal ganglia in human learning. Neuroscientist 2006;12:285-290.
55. Nambu A. A new dynamic model of the cortico-basal ganglia loop. Prog Brain Res 2004;143:461-466.
56. Lei W, Jiao Y, Del Mar N, Reiner A. Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J Neurosci 2004;24:8289-8299.
57. Nambu A, Tokuno 14, Inase M, Takada M. Corticosubthalamic input zones from forelimb representations of the dorsal and ventral divisions of the premotor cortex in the macaque monkey: comparison with the input zones from the primary motor cortex and the supplementary motor area. Neurosci Lett 1997; 239:13-16.
58. Cameras NS, Shammanh-Lagnado SJ, Silva BA, Ricardo JA. Somatotosensory inputs to the subthalamic nucleus: a combine retrograde and anterograde horseradish peroxidise study in the rat. Brain Res 1988;458:53-64.
59. Monakow KH, Akert K, Kunzle H. Projections of the precentral motor cortex and other cortical areas of the frontal lobe to the subthalamic nucleus in the monkey. Exp Brain Res 1978; 33:395-403.
60. Kita H, Tachibana Y, Nambu A, Chiken S. Balance of monosynaptic excitatory and disynaptic inhibitory responses of the globus pallidus induced after stimulation of the subthalamic nucleus in the monkey. J Neurosci 2005;25:8611-8619.
61. Obeso JA, Rodriguez-Oroz MC, Javier Blesa F, Guridi J. The globus pallidus pars externa and Parkinson's disease. Ready for prime time? Exp Neurol 2006;202:1-7.
62. Kita H. Globus pallidus external segment Prog Brain Res 2007;160:111-133.
63. Graybiel AM, Moratalla R. Dopamine uptake sites in the striatum are distributed differentially in striosome and matrix compartments. Proc Natl Acad Sci USA 1989;86:9020-9024.
64. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992;15:133-139.
65. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998;80:1-27.
66. Smith Y, Bennett BD, Bolamn JP, Parent A, Sadikot AF. Synaptic relationships between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum in monkey. J Comp Neurol 1994;344:1-19.
67. Abercrombie ED, DeBoer P, Heeringa MJ. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. Adv Pharmacol 1998;42:133-136.
68. Gonon F. Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo. J Neurosci 1997;17:5972-5978.
69. Descarries L, Watkins KC, Garcia S, Bosler O, Doucet G. Dual character, asynaptic and synaptic, of the dopamine innervation in adult rat neostriatum: a quantitative autoradiographic and immunocytochemical analysis. J Comp Neurol 1996;375:167-186.
70. Kawagoe KT, Garris PA, Wiedemann DJ, Wightman RM. Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 1992;51:55-64.
71. Hefti F, Enz A, Melamed E. Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology 1985;24:19-23.
72. Rodriguez M, Gonzalez J, Sabate M, Obeso J, Pereda E. Firing regulation in dopaminergic cells: effect of the partial degeneration of nigrostriatal system in surviving neurons. Eur J Neurosci 2003;18:53-60.
73. Rodriguez M, Pereda E, Gonzalez J, Abdala P, Obeso JA. How is firing activity of substantia nigra celis regulated? Relevance of pattern-code in the basal ganglia. Synapse 2003;49:216-225.
74. Rodriguez M, Morales I, Gonzalez-Mora JL, Gomez, I, Sabate M, Dopico JG, Rodriguez-Oroz MC, Obeso JA. Different levodopa actions on the extracellular dopamine pools in the rat striatum. Synapse 2007;61:61-71.
75. Bamford NS, Robinson S, Palmiter R, Joyce JA, Moore C, Meshul CK. Dopamine modulates release from corticostriatal terminals. J Neurosci 2004;24:9541-9552.
76. 3-calcineurin-signaling cascade. J Neurosci 2000;20:8987-8995.
77. Yung KK, Bolam JP, Smith AD, Hersch SM, Ciliax BJ, Levey AI. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 1995;65:709-730.
78. Picconi B, Gardoni F, Centonze D, et al. Abnormal Ca2ľmodulin-dependent proteinkinase II function mediates synaptic and motor deficits in experimentalparkinsonism. J Neurosci 2004; 24:5283-5291.
79. Hernández-Echeagaray E, Galarraga E, Bargas J. 3-α-chloroimperialine, a potent blocker of cholinergic presynaptic modulation of glutamatergic afferents in the rat neostriatum. Neuropharmacology 1998;37:1493-1503.
80. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007;30: 228-235.
81. Mallet N, Le Moine C, Charpier S, Gonon F. Feedforward inhibition of projection neurons by fast-spiking GABA interneurons in the rat striatum in vivo. J Neurosci 2005;25:3857-3869.
82. Graybiel AM, Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 2000;23(Suppl):S71-S77.
83. Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci 2000;23:120-126.
84. Bracci E, Centonze D, Bernardi G, Calabresi P. Dopamine excites fast-spiking interneurons in the striatum. J Neurophysiol 2002;87:2190-2194.
85. Calabresi P, Centonze D, Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci 2000;23(Suppl):S57-S63.
86. Bamford NS, Zhang H, Schmitz Y, et al. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 2004;42:653-663.
87. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007;445:643-647.
88. Mallet N, Ballion B, LeMoine C, Gonon F. Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. J Neurosci 2006;26:3875-3884.
89. Gardoni F, Picconi B, Ghiglieri V, et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 2006;26:2914-2922.
90. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003;6:501-506.
91. Sanchez-Gonzalez MA, Garcia-Cabezas MA, Rico B, Cavada C. The primate thalamus is a key target for brain dopamine. J Neurosci 2005;25:6076-6083.
92. Francois C, Savy C, Jan C, Tande D, Hirsch EC, Yelnik J. Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys, and in Parkinson's disease patients. J Comp Neurol 2000;425:121-129.
93. Kreiss DS, Anderson LA, Walters JR. Apomorphine and dopamine D-1 receptor agonists increase the firing rates of subthalamic nucleus neurons. Neuroscience 1996;72:863-867.
94. Anaya-Martinez V, Martinez-Marcos A, Martinez-Fong D, Aceves J, Erlij D. Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: implications for abnormal motor behavior. Neuroscience 2006;143:477-478.
95. Hazrati LN, Parent A. Projection from the external pallidum to the reticular thalamic nucleus in the squirrel monkey. Brain Res 1991;550:142-146.
96. Leviel V, Cheramy A, Glowinski J. Role of the dendritic release of dopamine in the reciprocal control of the two nigrostriatal dopaminergic pathways. Nature 1979;280:236-239.
97. Smith Y, Raju DV, Pare JF, Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci 2004;27:520-527.
98. Castle M, Aymerich MS, Sanchez-Escobar C, Gonzalo N, Obeso JA, Lanciego JL. Thalamic innervation of the direct and indirect basal ganglia pathways in the rat: Ipsi- and contralateral projections. J Comp Neurol 2005;483:143-153.
99. Mena-Segovia J, Bolam JP, Magill PJ. Pedunculopontine nucleus and basal ganglio: distant relatives or part of the same family? Trends Neurosci 2004;27:586-588.
100. Pahapill PA, Lozano AM. Pedunculopontine nucleus and Parkinson's disease. Brain 2000;123:1763-1783.
101. Whone AL, Moore RY, Piccini PP, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol 2003; 53:206-213.
102. Soares J, Kliem MA, Betarbet R, Greenamyre JT, Yamamoto B, Wichmann T. Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment. J Neurosci 2004;24:6417-6426.
103. Heimer G, Rivlin-Etzion M, Bar-Gad I, Goldberg JA, Haber SN, Bergman H. Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4- phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism. J Neurosci 2006;26:8101-8114.
104. Meissner W, Ravenscroft P, Reese R, et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 2006;22:5865-598.
105. Obeso JA, Rodriguez-Oroz M, Marin C, et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004;62(1 Suppl 1):S17-S30.
106. Bibbiani F, Costantini LC, Patel R, Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005;192:73-78.
107. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
108. Nutt GJ. Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa? Mov Disord 2007; 22:1-9.